How to Buy Glaukos Stock
Glaukos Corp
Glaukos is a medical device company located in California, United States, which is part of the Healthcare sector, and is traded under the ticker GKOS on the NYSE exchange.
Glaukos stock last closed at $184.53, up 0.59% from the previous day, and has increased 107.35% in one year. It has overperformed other stocks in the Medical Devices industry by 2.07 percentage points. Glaukos stock is currently +152.23% from its 52-week low of $73.16, and -2.88% from its 52-week high of $190.00.
There are currently 58.98M GKOS shares outstanding. The market value of GKOS is $10.88B. In the last 24 hours, 743,000 GKOS shares were traded.
How to Buy Glaukos Stock
Not sure how to invest in Glaukos stock? Here's how.
- Decide where to buy Glaukos stock: You need to choose an online brokerage, but don't worry - we've researched dozens of stock brokerages and apps to help you choose where to buy Glaukos stock.
- Create your brokerage account: Sign up for 0% commission trading with the highest-rated brokerage we've selected.
- Deposit funds into your investment account: Pick your method of payment and add your information.
- Evaluate Glaukos stock: The Glaukos ticker symbol is GKOS. Is Glaukos stock a good investment? Should you buy shares of GKOS? How do GKOS's underlying business fundamentals look? Do top analysts think Glaukos is a good buy? Why has GKOS's stock price moved recently? (Hint: Our stock research website can help you evaluate if GKOS is a good stock to buy).
- Make your GKOS purchase: Decide if you will purchase GKOS shares at the current market price or use a limit order to purchase GKOS stock at a particular price.
- Get updates on your GKOS position: Create a watchlist to watch your position in Glaukos shares.
Step 1: Decide where to buy Glaukos stock
You will need an online brokerage account in order to access the NYSE market and buy GKOS stock.
Our recommended brokerage: eToro
In our opinion, eToro is the best stock brokerage. eToro gives you:
- Invest in stocks with zero commissions: Invest without commissions.
- Buy fractional shares: Even if you don't have the money to buy a full share, you can still purchase the stock.
- Access to global markets: From Technology to Financial Services, New York to Hong Kong (for US users, only US stocks are available) — you can fill your portfolio with stocks from the world's leading stock exchanges.
- Social investing: eToro offers a community of more than 20 million users globally. Talk to, learn from, and copy the crypto trades of top investors.
- Security: eToro is a regulated and licensed fintech leader.
- Buy other assets: Such as ETFs and cryptos.
Get $10 towards your purchase of shares by creating an account with eToro today. This offer is only for US users.
Open eToro AccountStep 2: Create your brokerage account
Now that you've picked the best brokerage, the next step is to fill out some personal information so you are able to invest in GKOS today.
How to Set Up a New Brokerage Account on eToro
- Click here to get started.eToro is a multi-asset investment platform. The value of your investments may go up or down. Your capital is at risk.
- Enter your personal details to create a new trading account.
- Send your info by hitting the "Create Account" button. Get started with eToro today
Step 3: Deposit funds into your investment account
Now that you have filled out your info on one of the most highly reviewed stock apps, your next step is to transfer the money for your investment:
Check out the video below if you need help depositing money into your investment account.
Step 4: Evaluate Glaukos stock
After you have decided on the best place to buy Glaukos stock, it's critical to research their stock prior to investing, so you actually understand the risk and opportunity.
Overview of key GKOS info
Fundamentals of GKOS
WallStreetZen was designed to help everyday investors perform better fundamental analysis.
You can view all of the due diligence checks on GKOS's stock page.
Is GKOS stock undervalued?
You can use a variety of different financial metrics, analyses, models, and charts to gauge GKOS's intrinsic value.
Using relative valuations ratios:
- GKOS may be overvalued based on its P/B ratio of 15.95x, relative to Medical Devices industry P/B ratio of 3.36x
You can access more valuation analysis on GKOS's stock here.
GKOS Financial Health Summary
Passed Health Checks:
- GKOS has a low debt to equity ratio of 0.35.
- There are more short-term assets than short-term liabilities on the GKOS balance sheet.
- Total GKOS debt is lower than 5 years ago, relative to shareholder equity.
- GKOS has $289.34M in cash and short term investments. This is sufficient to cover its annual cash burn of $12.20M.
- GKOS has cash burn of 12196000. It has enough cash and short-term investments to cover this for at least one year.
- There are more short-term assets than long-term liabilities on the GKOS balance sheet.
Failed Health Checks:
- GKOS profit margin has gone down from -21.4% to -30.7% in the past year.
Is it a good time to buy GKOS stock, according to Wall Street analysts?
Out of 11 Equities analysts who give forecasts on GKOS, the consensus analyst rating on Glaukos is a Strong Buy
It's important to note that analyst forecasts are not stock recommendations, nor are they financial advice.
Most Recent GKOS Analyst Recommendations
Richard Newitter, a top 11% analyst from Truist Securities maintains GKOS with a strong buy rating and raises their GKOS price target from $180.00 to $215.00, on Jul 30, 2026.
Larry Biegelsen, a top 13% analyst from Wells Fargo maintains GKOS with a strong buy rating and raises their GKOS price target from $138.00 to $178.00, on Jul 30, 2026.
David Saxon, a top 22% analyst from Needham maintains GKOS with a buy rating and raises their GKOS price target from $150.00 to $201.00, on Jul 30, 2026.
Ryan Zimmerman, a top 14% analyst from BTIG maintains GKOS with a strong buy rating and raises their GKOS price target from $164.00 to $193.00, on Jul 30, 2026.
BTIG's Ryan Zimmerman raised their price target on Glaukos (NYSE: GKOS) by 17.7% from $164 to $193 on 2026/07/30. The analyst maintained their Strong Buy rating on the stock.
Glaukos reported its Q2 2026 earnings.
Raising their price target, Zimmerman called the quarter's results "above and beyond," led by iDose revenue of $74M, up 138.7% Y/Y, and Epioxa revenue of $11M in its first full commercial quarter.
Glaukos management continues approach guidance prudently, the analyst noted, particularly because Epioxa has the potential to ramp up revenue faster.
Earnings Report
For Q2 2026, Glaukos reported:
- EPS of $(0.14), which beat the Zacks Consensus Estimate of f$(0.28) and Q2 2025's $(0.24).
- Revenue of $185.6M, which beat the Zacks Consensus Estimate by 24.1% and was up 50% Y/Y.
For FY 2026, management guided:
- EPS of $(0.57).
- Revenue of $680M to $700M.
Chairman & CEO Thomas Burns commented: “Our record second quarter results reflect successful global execution across our key global commercial and development priorities, leaving us well positioned to sustain our strong growth momentum driven by two transformational growth drivers in iDose TR and Epioxa.
“We continue to successfully advance our robust pipeline of novel, dropless platform technologies designed to meaningfully advance the standard of care and improve outcomes for patients suffering from chronic eye diseases.”
Danielle Antalffy, a bottom 4% analyst from UBS assumes GKOS with a hold rating and announces their GKOS price target of $150.00, on Jul 28, 2026.
You can dig deeper into what analysts are saying on the Glaukos stock forecast page.
GKOS Trading Indicators
How is GKOS performing as a company?
Last year, GKOS revenue was $612.84M. During the past 5 year, GKOS's revenue has gone up by 16.62% per year. This was faster than the Medical Devices industry average of 8.8%.
You can research GKOS's earnings and revenue performance here.
Who is buying/selling GKOS?
In the past 12 months, insiders at GKOS have bought more shares than they have sold.
Joseph E. Gilliam, COO;Pres of GKOS, was the latest GKOS insider to buy. They bought $484,600.00 worth of GKOS shares on Aug 11, 2026.
Learn more about who owns GKOS stock here.
Can I rely on GKOS as an income stream?
No, Glaukos doesn't provide an income stream by paying out dividends.
Get opinions from other traders
One of the reasons eToro is our favorite brokerage is because of its social trading community.
Click below to see what other community members have to say.
Step 5: Make your GKOS purchase
There are two primary types of orders:
- Market order: A market order is an order to buy or sell a security at the best available price.
Market orders are mostly sufficient. - Limit order: A limit order lets you buy or sell a security at a specific price (or better).
If you want to make sure you're buying or selling at a given dollar amount limit, place a limit order.
Hit the Open button and your broker will place your order.
If you require more assistance buying stocks on eToro, click the how to video below:
Step 6: Get updates on your GKOS position
Now that you own some GKOS shares, you'll want to keep up with your stock purchase.
Start a watchlist to keep tabs on your GKOS stock.
GKOS Feed
How to Buy Stock in Glaukos
To reiterate, here are the 6 steps you need to take to buy Glaukos stock right now:
- Decide where to buy Glaukos stock
- Create your brokerage account
- Deposit funds into your investment account
- Evaluate Glaukos stock
- Make your GKOS purchase
- Get updates on your GKOS position
If you are looking for a online brokerage, eToro is our recommended option.
Get Started with eToro TodayIf you would like to get the latest scoop on your investment in Glaukos, add GKOS to your watchlist by clicking the button below.
Other Articles You Might Enjoy
FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterInformation is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.